
A randomized clinical trial in Tehran assessed the impact of adding bimatoprost 0.03% to 308-nm excimer laser therapy for facial vitiligo. The combination significantly improved VASI scores (p ≤ 0.001) compared to monotherapy. VASS and SAI scores also showed greater improvement. Mild side effects included hypertrichosis and erythema. Bimatoprost may enhance outcomes in treatment-resistant vitiligo.
Like
Save
Share